PacBio announced Q3 2026 revenue of $40.6 million, a slight increase from the prior-year period, alongside the departure of its Chief Financial Officer, Jim Gibson. The company also updated its full-year 2026 revenue guidance to a range of $155 million to $160 million and highlighted new strategic collaborations in clinical and AI-driven research.
Key Details
- Q3 2026 Financials: Revenue reached $40.6 million, up from $38.4 million in Q3 2025. GAAP net loss was $37.8 million ($0.12 per share), and GAAP gross margin was 33%, down from 41% in the prior-year quarter.
- Management Transition: CFO Jim Gibson has stepped down. Mark Van Oene (President and CEO) has been appointed interim CFO, and Bill Meyer has been appointed Chief Accounting Officer as the company begins a search for a new CFO.
- Updated 2026 Guidance: PacBio now expects full-year 2026 revenue to be between $155 million and $160 million.
- Operational Metrics: The company delivered 15 Revio systems and 35 Vega systems in the quarter and announced new partnerships with GeneDx, Verily Health, and TychoBio to expand the use of its HiFi sequencing technology.